Skip to content

EBITDA at other companies

Immunome logo
ImmunomeIMNM
-$58.73M-33.4%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
-$15.37M+38.2%
Erasca, Inc. logo
Erasca, Inc.ERAS
-$187.19M-438%
Abbott logo
AbbottABT
Guardant Health logo
Guardant HealthGH
Natera, Inc. logo
Natera, Inc.NTRA

Other financials

Income statement

See full
Revenue$40.8M+28.1%
Operating income-$135.8M+11.6%
Net income-$93.2M+12.3%
EPS (diluted)-$2.29+26.1%

Balance sheet

See full
Cash & equivalents$76.3M-44.4%
Total debt$51.0M-20.7%
Total equity$2.5B+3.6%
Total assets$2.8B-1.5%

Cash flow

See full
Operating cash flow-$87.0M+8.4%
CapEx$503.0K+711%
Free cash flow-$87.5M+8.0%

Valuation

See full
Market cap$2.62B+145%
Enterprise value$2.6B+164%
P/S16.8×+8.6×

Profitability

See full
Operating margin-348.7%-153pp
Net margin-253.2%-115pp
FCF margin-187.2%-60.4pp

Returns & leverage

See full
Return on equity-16.1%
Debt / equity0.0×
Current ratio11.7×+2.0×

Where this comes from

Calculated from GRAIL, Inc.’s reported figures.

$135.8Mebit+
$37.7MDepreciation Depletion & Amortization
=-$98.08M

The official record: GRAIL, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about GRAIL, Inc.'s ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GRAIL, Inc.'s EBITDA?
GRAIL, Inc. (GRAL) reported EBITDA of -$98.08M in Q1 2026.
How has GRAIL, Inc.'s EBITDA changed year-over-year?
GRAIL, Inc.'s EBITDA increased by 14.2% year-over-year, from -$114.33M to -$98.08M.
What is the long-term trend for GRAIL, Inc.'s EBITDA?
Over 3 years (2022 to 2025), GRAIL, Inc.'s EBITDA has grown at a -56.3% compound annual growth rate (CAGR), from -$5.29B to -$440.37M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.